3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Glioma
4
Non-Muscle Invasive Bladder Neoplasms
3
Wilms Tumor
2
Urinary Bladder Neoplasms
2
Rhabdoid Tumor
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Central Nervous System Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Interventions
Cyclophosphamide
10
fludarabine
7
pomalidomide
5
pembrolizumab
5
Dexamethasone
5
daratumumab
4
obinutuzumab
3
glofitamab
3
fludarabine phosphate
3
abemaciclib
3
Rituximab
3
Melphalan
3
Immunotherapy, Adoptive
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
pirtobrutinib
2
palbociclib
2
cemiplimab
2
blinatumomab
2
Temozolomide
2
Sirolimus
2
Oxaliplatin
2
Nivolumab
2
Mesna
2
Letrozole
2
Injections
2
Gemcitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
erdafitinib
×
30 days
×
Clear all
No trials found.